[{"id":"678c2f57-c2a1-4d53-9b3f-1c28268db167","acronym":"","url":"https://clinicaltrials.gov/study/NCT05174650","created_at":"2022-01-03T15:00:36.712Z","updated_at":"2025-02-25T13:36:03.205Z","phase":"Phase 2","brief_title":"Treatment of Atezolizumab and Derazantinib in Patients With Advanced iCCA With FGFR2 Fusions/Rearrangements","source_id_and_acronym":"NCT05174650","lead_sponsor":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","biomarkers":" FGFR2","pipe":" | ","alterations":" FGFR2 fusion","tags":["FGFR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR2 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • derazantinib (ARQ 087)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 04/20/2022","start_date":" 04/20/2022","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 08/01/2026","study_completion_date":" 08/01/2026","last_update_posted":"2024-07-24"},{"id":"45f9e4a5-fb7c-4d84-a994-fb30e1410536","acronym":"FIDES-01","url":"https://clinicaltrials.gov/study/NCT03230318","created_at":"2021-01-17T17:21:24.827Z","updated_at":"2025-02-25T13:34:55.963Z","phase":"Phase 2","brief_title":"Derazantinib in Subjects With FGFR2 Gene Fusion-, Mutation- or Amplification- Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma","source_id_and_acronym":"NCT03230318 - FIDES-01","lead_sponsor":"Basilea Pharmaceutica","biomarkers":" FGFR2","pipe":" | ","alterations":" FGFR2 mutation • FGFR2 fusion","tags":["FGFR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR2 mutation • FGFR2 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e derazantinib (ARQ 087)"],"overall_status":"Completed","enrollment":" Enrollment 148","initiation":"Initiation: 09/28/2017","start_date":" 09/28/2017","primary_txt":" Primary completion: 10/25/2022","primary_completion_date":" 10/25/2022","study_txt":" Completion: 10/25/2022","study_completion_date":" 10/25/2022","last_update_posted":"2023-12-19"},{"id":"9348086e-e891-40b0-a92b-8bc10d06743b","acronym":"FIDES-02","url":"https://clinicaltrials.gov/study/NCT04045613","created_at":"2021-01-17T17:51:34.154Z","updated_at":"2025-02-25T13:35:26.193Z","phase":"Phase 1b/2","brief_title":"Derazantinib and Atezolizumab in Patients With Urothelial Cancer","source_id_and_acronym":"NCT04045613 - FIDES-02","lead_sponsor":"Basilea Pharmaceutica","biomarkers":" FGFR2","pipe":" | ","alterations":" FGFR2 mutation • FGFR3 mutation","tags":["FGFR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR2 mutation • FGFR3 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • derazantinib (ARQ 087)"],"overall_status":"Completed","enrollment":" Enrollment 95","initiation":"Initiation: 08/02/2019","start_date":" 08/02/2019","primary_txt":" Primary completion: 10/04/2022","primary_completion_date":" 10/04/2022","study_txt":" Completion: 10/04/2022","study_completion_date":" 10/04/2022","last_update_posted":"2023-10-13"},{"id":"7712e249-c771-42c3-9329-6505eef60157","acronym":"","url":"https://clinicaltrials.gov/study/NCT01752920","created_at":"2021-01-18T07:41:42.842Z","updated_at":"2025-02-25T16:12:56.841Z","phase":"Phase 1/2","brief_title":"Phase 1/2 Study of Derazantinib (ARQ 087) in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations","source_id_and_acronym":"NCT01752920","lead_sponsor":"Basilea Pharmaceutica","biomarkers":" FGFR2","pipe":" | ","alterations":" FGFR2 fusion","tags":["FGFR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR2 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e derazantinib (ARQ 087)"],"overall_status":"Completed","enrollment":" Enrollment 119","initiation":"Initiation: 12/10/2012","start_date":" 12/10/2012","primary_txt":" Primary completion: 08/28/2018","primary_completion_date":" 08/28/2018","study_txt":" Completion: 08/28/2018","study_completion_date":" 08/28/2018","last_update_posted":"2023-06-05"}]